Angiogenesis is the growth of new blood vessels from pre-existing vessels and involves proliferation of microvascular endothelial cells (MEC). VEGF is a major promoter of angiogenesis and mediates angiogenic effects through interaction with VEGF receptor-2 (VEGF-R2). We have demonstrated that MEC derived from human myometrium (MMEC) constitutively express estrogen receptor-β (ERβ), while ERα varies between subjects and is only expressed in approximately 60% of MEC isolates 1 . 17β-estradiol (E) upregulates VEGF-R2 and promotes MEC proliferation in the ERα-expressing isolates, but not in ERα negative MMEC 2 . The aim of the present study was to determine whether ERα mediates upregulation of VEGF-R2 and the angiogenic effects of E in ERα-expressing adult human MEC using the novel ERα-selective ligands, PPT and R,R-THC 3 . Myometrial MEC were isolated from hysterectomy tissue obtained from ovulating women, cultured and used between passages 1-3 (purity >98% CD31+ cells) 4 . ERα and VEGF-R2 expression were measured by flow cytometry using an ERα antibody and biotin-rhVEGF 165 binding respectively 2 . MEC proliferation was determined by MTS bioassay 2 . We first tested the activity of PPT and R,R-THC on a breast tumour cell line known to express wildtype ERα (MCF-7) and demonstrated that both ligands significantly increased proliferation in a similar manner to E, an effect blocked by the nonspecific ER antagonist, ICI 182,780. Neither PPT or R,R-THC stimulated proliferation of the ERα negative cell line MDA-DB-453. In ERα+ MMEC, PPT and E increased VEGF binding in a dose-dependent manner, but had no effect on ERα negative MMEC samples. PPT, R,R-THC and E significantly augmented VEGF-induced MMEC proliferation in ERα positive MMEC (P< 0.05) but not ERα negative MMEC. These data confirm that the angiogenic effects of E on MMEC are due to upregulation of VEGF-R2 and are mediated by ERα rather than ERβ. 
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